New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ropivacaine hydrochloride 10 mg/ml equivalent to ropivacaine 8.85 mg/ml;   - solution for injection - 10 mg/ml - active: ropivacaine hydrochloride 10 mg/ml equivalent to ropivacaine 8.85 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - analgesia (adults and children over 12 years of age) · continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain · field block (minor nerve block and infiltration) · continuous peripheral nerve block infusion or intermittent injections for postoperative pain management · continuous wound infusion for postoperative pain management (adults only) analgesia (children aged 0-12 years of age) · caudal epidural block in neonates (>37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years · continuous epidural infusion in infants (>30 days and over 2500 g weight) and children up to and including 12 years · peripheral nerve block in children aged 1 up to and including 12 years for peri- and postoperative pain management

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ropivacaine hydrochloride 2 mg/ml equivalent to ropivacaine 1.77 mg/ml;   - solution for injection - 2 mg/ml - active: ropivacaine hydrochloride 2 mg/ml equivalent to ropivacaine 1.77 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - analgesia (adults and children over 12 years of age) · continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain · field block (minor nerve block and infiltration) · continuous peripheral nerve block infusion or intermittent injections for postoperative pain management · continuous wound infusion for postoperative pain management (adults only) analgesia (children aged 0-12 years of age) · caudal epidural block in neonates (>37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years · continuous epidural infusion in infants (>30 days and over 2500 g weight) and children up to and including 12 years · peripheral nerve block in children aged 1 up to and including 12 years for peri- and postoperative pain management

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ropivacaine hydrochloride 5 mg/ml equivalent to ropivacaine 4.43 mg/ml;   - solution for injection - 5 mg/ml - active: ropivacaine hydrochloride 5 mg/ml equivalent to ropivacaine 4.43 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - analgesia (adults and children over 12 years of age) · continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain · field block (minor nerve block and infiltration) · continuous peripheral nerve block infusion or intermittent injections for postoperative pain management · continuous wound infusion for postoperative pain management (adults only) analgesia (children aged 0-12 years of age) · caudal epidural block in neonates (>37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years · continuous epidural infusion in infants (>30 days and over 2500 g weight) and children up to and including 12 years · peripheral nerve block in children aged 1 up to and including 12 years for peri- and postoperative pain management

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ropivacaine hydrochloride 7.5 mg/ml equivalent to ropivacaine 6.64 mg/ml;   - solution for injection - 7.5 mg/ml - active: ropivacaine hydrochloride 7.5 mg/ml equivalent to ropivacaine 6.64 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - analgesia (adults and children over 12 years of age) · continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain · field block (minor nerve block and infiltration) · continuous peripheral nerve block infusion or intermittent injections for postoperative pain management · continuous wound infusion for postoperative pain management (adults only) analgesia (children aged 0-12 years of age) · caudal epidural block in neonates (>37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years · continuous epidural infusion in infants (>30 days and over 2500 g weight) and children up to and including 12 years · peripheral nerve block in children aged 1 up to and including 12 years for peri- and postoperative pain management

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - paracetamol 10 mg/ml;   - solution for injection - 10 mg/ml - active: paracetamol 10 mg/ml   excipient: cysteine mannitol water for injection - for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - flumazenil 0.1 mg/ml - solution for injection - 0.5 mg/5ml - active: flumazenil 0.1 mg/ml excipient: acetic acid disodium edetate dihydrate nitrogen sodium chloride sodium hydroxide water for injection - flumazenil injection is indicated for reversal of the centrally sedative effects of benzodiazepines. it should therefore be used in anaesthesia and intensive care in the following indications: in anaesthesia · termination of general anaesthesia induced and maintained with benzodiazepines in inpatients. · reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures in both inpatients and outpatients. · reversal of paradoxical reactions due to benzodiazepines. in intensive care and in the management of unconsciousness of unknown origin · for the diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose. · as a diagnostic measure in unconsciousness of unknown origin to differentiate between involvement of benzodiazepines, other medicines or drugs or brain damage. · may also be used for specific reversal of the central effects of benzodiazepines in drug or medicine overdose (return to spontaneous respiration and consciousness in order to render intubation unnecessary or allow extubation).

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - flumazenil 0.1 mg/ml - solution for injection - 1 mg/10ml - active: flumazenil 0.1 mg/ml excipient: acetic acid disodium edetate dihydrate nitrogen sodium chloride sodium hydroxide water for injection - flumazenil injection is indicated for reversal of the centrally sedative effects of benzodiazepines. it should therefore be used in anaesthesia and intensive care in the following indications: in anaesthesia · termination of general anaesthesia induced and maintained with benzodiazepines in inpatients. · reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures in both inpatients and outpatients. · reversal of paradoxical reactions due to benzodiazepines. in intensive care and in the management of unconsciousness of unknown origin · for the diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose. · as a diagnostic measure in unconsciousness of unknown origin to differentiate between involvement of benzodiazepines, other medicines or drugs or brain damage. · may also be used for specific reversal of the central effects of benzodiazepines in drug or medicine overdose (return to spontaneous respiration and consciousness in order to render intubation unnecessary or allow extubation).

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - egg lecithin 1.2%{relative} (as a component in fish oil);  ; fish oil 10%{relative} (highly refined); glycerol 2.5%{relative} (as a component in fish oil) - emulsion for infusion - active: egg lecithin 1.2%{relative} (as a component in fish oil)   fish oil 10%{relative} (highly refined) glycerol 2.5%{relative} (as a component in fish oil) excipient: sodium hydroxide sodium oleate water for injection - for use as a fraction of the lipid emulsion component for total parenteral nutrition, providing supplements of long chain omega-3-fatty acids especially eicosapentanoic and docosahexanoic acid when oral or enteral nutrition is impossible, insufficient or contraindicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons); sodium chloride 0.9%; hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) - solution for infusion - active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) sodium chloride 0.9% excipient: hydrochloric acid sodium hydroxide water for injection active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - water for injection 100% - solution for injection - active: water for injection 100% - water for injections is used to dissolve or dilute substances or preparations for parenteral administration. water for injections may also be used as an irrigating solution for small wounds or during minor surgical procedures.